Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Aptah Bio logo — The next generation of RNA therapeutics for age-related dise...

Aptah Bio

The next generation of RNA therapeutics for age-related diseases

Founded 2019 United States San Carlos, United States 12 employees Seed Total: $3.40M Biotechnology, Health and Wellness +3

General Information

Company Name Aptah Bio
Founded Year 2019
Location United States San Carlos, United States
Founders / Decision Makers
Team member
Employees 12
Industries Biotechnology, Health and Wellness, Life Sciences +2
Funding Stage Seed
Business Model B2B, Platform
Revenue Model Licensing, Performance Based, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Aptah Bio. To contact Aptah Bio, visit aptah-bio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Aptah Bio compare?

A PDF of Aptah Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Aptah Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Aptah Bio

Aptah Bio, founded in 2019 and headquartered in the United States, is making strides in the biotechnology and pharmaceutical sectors. The company's slogan, "The next generation of RNA therapeutics for age-related diseases," encapsulates its mission to eradicate ailments associated with aging.

With a strategic aim to transform the healthcare landscape, Aptah Bio has developed an innovative therapy that serves as a genome-wide transcription modulator. This pioneering compound is the first of its kind, designed to correct various mRNAs and toxic proteins, potentially revolutionizing treatments for age-related diseases.

The company's recent progress was bolstered by a $3.40M Seed Round investment from Vesper Ventures SA on January 20, 2021. Positioned at the intersection of biotechnology, health, and life sciences, Aptah Bio stands primed to capture a stake in a multi-billion dollar market by addressing critical health challenges.

Business keywords: RNA therapeutics, Age-related diseases, Neurodegenerative diseases, Pharmaceuticals, Biopharmaceuticals, Genome-wide transcription modulation, Patent attorneys, Biotech startup, Economic impact, Global health, Aging population, Epidemiology, Investment potential

Services & Products

Developing RNA-based therapies
Restoring transcription fidelity
Reducing tumor heterogeneity
Enhancing existing cancer therapies

Target Customers

Oncologists Cancer treatment centers Pharmaceutical companies Biotechnology investors Patients with aggressive cancer types

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round $3.40M 1
Vesper Ventures SA
Vesper Ventures SA
20 Jan 2021

Aptah Bio Alternatives & Competitors

View All Alternatives
Aptah Bio vs
Neogene Therapeutics
Neogene Therapeutics The Netherlands

Pushing the frontier by pioneering next-generation engineered T cell receptor therapies for solid ca...

Acquired
45 employees
Biotechnology, Health Care
Aptah Bio vs
Eisai US
Eisai US United States

Breaking through in the therapeutic areas of oncology and neurology. View our community guidelines:...

2910 employees
Biotechnology, Health Care
Aptah Bio vs
Qualisure Diagnostics Inc.
Qualisure Diagnostics Inc. Canada

Deploying AI-enabled molecular diagnostics globally through decentralized testing and centralized in...

Seed
10 employees
Biotechnology, Health Care
View all alternatives

FAQ About Aptah Bio

The next generation of RNA therapeutics for age-related diseases
Aptah Bio was founded in 2019.
Aptah Bio is headquartered in San Carlos, United States.
Aptah Bio operates in Biotechnology, Health and Wellness, Life Sciences, Pharmaceutical and Clean Energy. Its work centres on RNA therapeutics, Age-related diseases, Neurodegenerative diseases and Pharmaceuticals. Its customers include Oncologists, Cancer treatment centers and Pharmaceutical companies.
Aptah Bio has a B2B and Platform business model. Its revenue comes from Licensing, Performance Based and Product Sales.
Aptah Bio has approximately 12 employees.
Aptah Bio has completed 1 funding round, raising a total of $3.40M. The latest funding stage is Seed.
Aptah Bio offers: Developing RNA-based therapies, Restoring transcription fidelity, Reducing tumor heterogeneity, Enhancing existing cancer therapies.
Top alternatives and competitors to Aptah Bio include Neogene Therapeutics, Eisai US, Qualisure Diagnostics Inc., Sapience Therapeutics, Inc., ImmunAbs Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Aptah Bio and Neogene Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Aptah Bio, https://bouncewatch.com/company/aptah-bio, updated 20 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout